ALLMedicine™ Acne Vulgaris Center

Jun 26th, 2022 - To investigate the correlation among different investigators (intra-rater variation) in the assessment of acne vulgaris severity using Acne Grading System (AGS), International Improvement Grading System (IIGS), Investigator Global Assessment of ac...

Jun 25th, 2022 - A frequent inflammatory pilosebaceous disorder that affects 80-90% of teenagers, acne vulgaris is still a concern for dermatologists and other doctors in the field of medicine. Acne has a significant psychosocial impact and is responsible for a bi...

Jun 24th, 2022 - The purpose of this study is to evaluate the onset, duration, efficacy and safety of the laser for the treatment of acne vulgaris.

Jun 23rd, 2022 - Multiple patient-reported outcome measures (PROMs) for health-related quality of life (HRQoL) exist for patients with acne. However, little is known about the content validity and other measurement properties of these PROMs. To systematically revi...

Jun 15th, 2022 - Practice Essentials Acne fulminans (AF), also known as acne maligna, was originally described as acute febrile ulcerative acne conglobata (AC). In 1958, at a meeting of the Detroit Dermatological Society, Burns and Colville presented a 16-year-old...

Sep 22nd, 2021 - Management of acne vulgaris: summary of NICE guidance.|2021|Xu J,Mavranezouli I,Kuznetsov L,Stephen Murphy M,Healy E,|

May 22nd, 2018 - The Guidelines for the Treatment of Acne Vulgaris of the Japanese Dermatological Association was first published in Japanese in 2008 and revised in 2016 and 2017. These guidelines (GL) indicate the standard acne treatments in Japan and address pha...

May 3rd, 2013 - Acne vulgaris is one of the most common skin conditions in children and adolescents. The presentation, differential diagnosis, and association of acne with systemic pathology differs by age of presentation. Current acknowledged guidelines for the ...

Jun 24th, 2022 - The purpose of this study is to evaluate the onset, duration, efficacy and safety of the laser for the treatment of acne vulgaris.

Jun 9th, 2022 - Vitamin D is known to be related with calcium and bone metabolism. Recently, vitamin D has been shown to play an important role in innate and acquired immunity, cytokine release, inflammatory response, and may be associated with a reduced risk of ...

Jun 9th, 2022 - Acne scar is a common complication of acne vulgaris (AV). Early and effective treatment of AV has a crucial role in managing both acne and acne scarring. Oral isotretinoin (OI) is a widely preferred agent in treating moderate and severe AV worldwi...

Jun 8th, 2022 - Acne vulgaris is a common cutaneous inflammatory condition of sebaceous follicles that can profoundly affect patients' quality of life, especially at a young age. In this context the use of teledermatology can potentially reduce the healthcare cos...

Jun 3rd, 2022 - Antibiotic resistance is a public health problem that worsens the more physicians prescribe standard dose antibiotics for acne. Regardless of race, acne vulgaris is one of the most common dermatologic conditions among pediatric populations. As suc...

Feb 17th, 2022 - Adbry (tralokinumab) Tralokinumab is an interleukin-13 (IL-13) inhibitor that blocks IL-13–induced responses (eg, release of proinflammatory cytokines, chemokines, IgE). It is indicated for moderate-to-severe atopic dermatitis in adults who are no...

Feb 7th, 2022 - Acne vulgaris is an extremely common dermatologic disease affecting 40 to 50 million individuals in the United States each year, with a prevalence of 85% in adolescents and young adults aged 12 to 24 years. For some patients, the disease may persi.

Dec 1st, 2021 - To the Editor: Minocycline is a commonly prescribed semisynthetic tetracycline derivative used for long-term treatment of acne vulgaris. 1 Given the continued popularity of minocycline and other tetracyclines in treating acne, more adverse side eff.

Nov 4th, 2021 - To the Editor: Photodynamic therapy (PDT) is a US Food and Drug Administration–approved treatment for actinic keratosis (AK). It also commonly is administered off label for basal cell carcinoma, Bowen disease, photoaging, and acne vulgaris and is.

Oct 13th, 2021 - Opzelura FDA Approved for Atopic Dermatitis Incyte Corporation announces US Food and Drug Administration (FDA) approval of Opzelura (ruxolitinib) cream 1. 5% for the short-term and noncontinuous chronic treatment of mild to moderate atopic dermatit.